Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 243

recruiting
3 970
countries
28
conditions
2 124

10 522 trials match your criteria

Study on Adding Diclofenac to PD-1 Inhibitor Therapy for Patients with Metastatic Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Diclofenac Sodium

Psychotic disorder+1

Recruiting

Study on Long-Term Safety of KarXT (Trospium Chloride, Xanomeline Tartrate) for Patients with Alzheimer's-Related Psychosis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride

Study on the Effectiveness of Doxorubicin, Ifosfamide, and Dacarbazine in High-Risk Patients with Resectable Soft-Tissue Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine

Ichthyosis

Recruiting

Study on the Effects of Injectable Gentamicin for Patients with Moderate to Severe Congenital Ichthyosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gentamicin Sulfate

Myocarditis+2

Recruiting

Study on the Use of Methylprednisolone Sodium Succinate for Treating Patients with Acute Myocarditis and Mildly Reduced Heart Function

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Sodium Chloride

Study on Bevacizumab for Patients with Symptomatic Cerebral Arteriovenous Malformations

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Study on Dapagliflozin for Slowing Kidney Disease in Adolescents and Young Adults with Alport Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Dapagliflozin

Long-term safety study of rebisufligene etisparvovec gene therapy in patients previously treated for Mucopolysaccharidosis type IIIA

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Rebisufligene Etisparvovec

Study on the Safety and Effectiveness of Rebisufligene Etisparvovec for Patients with Mucopolysaccharidosis Type IIIA

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Rebisufligene Etisparvovec

B-cell lymphoma+2

Recruiting

Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tisagenlecleucel

Study on the Safety and Tolerability of Treprostinil Sodium for Children with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Treprostinil Sodium

Study on Bevacizumab, Encorafenib, and Cetuximab for Patients with BRAF-V600E Mutated Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.